Oxia develops Endogenous Repair Modulators (ERM), a new class of medicines that activate the body’s innate cellular repair mechanisms to extend healthspan and improve recovery from injury and disease. Leveraging over 20 years of research from Baylor College of Medicine, its platform targets the body’s natural healing biology, aiming to reduce disability and lessen the burden on patients, families, and healthcare systems.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for chronic diseases and acute injuries focus on managing symptoms rather than repairing damaged tissue, leading to prolonged disability, high healthcare costs, and limited recovery of function.
Solution
Oxia is developing Endogenous Repair Modulators (ERM), a novel class of medicines that activate the body’s innate cellular repair programs. By targeting epigenetic pathways that coordinate protection, regeneration, and restoration across multiple organs, ERM therapies aim to reverse tissue damage and extend healthspan. The platform supports several delivery formats—including intravenous, oral, nasal spray, and topical—to address both acute injuries (e.g., stroke, myocardial infarction) and chronic conditions (e.g., renal failure, fibrosis). Oxia’s approach leverages two decades of research from Baylor College of Medicine and a robust patent portfolio to create scalable, disease‑agnostic treatments that move care from symptom management toward true recovery.
Target Audience
Primary customers are pharmaceutical partners and healthcare providers seeking disease‑modifying therapies for acute injury and chronic organ failure, as well as patients and families affected by these conditions.
Features
- Targets core regenerative pathways to activate endogenous repair mechanisms at the cellular level
- Modular delivery options (IV, oral tablets, nasal spray, topical) for acute and chronic indications
- Pipeline includes therapies for stroke, heart attack/heart failure, renal failure, and fibrosis
- Scalable synthetic chemistry and strong composition‑of‑matter patents protect both stimulators and inhibitors
- Pre‑clinical and IND‑enabling programs aligned with FDA regulatory expectations for early‑stage clinical trials